These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1710457)

  • 1. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.
    Morris G; Mistry JS; Jani JP; Sebti SM; Lazo JS
    Biochem Pharmacol; 1991 Jun; 41(11):1559-66. PubMed ID: 1710457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
    Sebti SM; Jani JP; Mistry JS; Gorelik E; Lazo JS
    Cancer Res; 1991 Jan; 51(1):227-32. PubMed ID: 1703034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo circumvention of human colon carcinoma resistance to bleomycin.
    Jani JP; Mistry JS; Morris G; Davies P; Lazo JS; Sebti SM
    Cancer Res; 1992 May; 52(10):2931-7. PubMed ID: 1374681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
    Mistry JS; Jani JP; Morris G; Mujumdar RB; Reynolds IJ; Sebti SM; Lazo JS
    Cancer Res; 1992 Feb; 52(3):709-18. PubMed ID: 1370650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA.
    Wassermann K; Zwelling LA; Lown JW; Hartley JA; Nishikawa K; Lin JR; Newman RA
    Cancer Res; 1990 Mar; 50(6):1732-7. PubMed ID: 1689610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64.
    Jani JP; Mistry JS; Morris G; Lazo JS; Sebti SM
    Oncol Res; 1992; 4(2):59-63. PubMed ID: 1375852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
    Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
    Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity of bleomycin hydrolase.
    Sebti SM; DeLeon JC; Ma LT; Hecht SM; Lazo JS
    Biochem Pharmacol; 1989 Jan; 38(1):141-7. PubMed ID: 2462878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial single-strand DNA damage and cellular pharmacokinetics of bleomycin A2.
    Lazo JS; Schisselbauer JC; Meandzija B; Kennedy KA
    Biochem Pharmacol; 1989 Jul; 38(13):2207-13. PubMed ID: 2472141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of bleomycin resistance in a human oral squamous carcinoma cell line and characterisation of bleomycin-resistant and -sensitive clones.
    Urade M; Ogura T; Uematsu T; Takahashi Y; Kishimoto H; Yoshioka W
    Eur J Cancer B Oral Oncol; 1994 Nov; 30B(6):409-14. PubMed ID: 7536509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
    Pei Z; Calmels TP; Creutz CE; Sebti SM
    Mol Pharmacol; 1995 Oct; 48(4):676-81. PubMed ID: 7476893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteine proteinase inhibitors reduce malignant melanoma cell invasion in vitro.
    Bjørnland K; Buø L; Kjønniksen I; Larsen M; Fodstad O; Johansen HT; Aasen AO
    Anticancer Res; 1996; 16(4A):1627-31. PubMed ID: 8712680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of bleomycin hydrolase by an epitope-specific antibody.
    Morris G; Mistry JS; Jani JP; Mignano JE; Sebti SM; Lazo JS
    Mol Pharmacol; 1992 Jul; 42(1):57-62. PubMed ID: 1378925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further characterization of bleomycin-resistant HeLa cells and analysis of resistance mechanism.
    Urade M; Sugi M; Matsuya T
    Jpn J Cancer Res; 1988 Apr; 79(4):491-500. PubMed ID: 2454906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism.
    Pron G; Mahrour N; Orlowski S; Tounekti O; Poddevin B; Belehradek J; Mir LM
    Biochem Pharmacol; 1999 Jan; 57(1):45-56. PubMed ID: 9920284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleomycin hydrolase activity and cytotoxicity in human tumors.
    Lazo JS; Boland CJ; Schwartz PE
    Cancer Res; 1982 Oct; 42(10):4026-31. PubMed ID: 6179595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined effect of bleomycin and SDB-ethylenediamine, a synthetic isoprenoid, on oral squamous carcinoma cell lines and transplantable nude mouse tumors].
    Takahashi Y; Urade M; Kishimoto H; Arimoto T; Yanagisawa T; Yoshioka W
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):883-7. PubMed ID: 7540824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of antioxidant enzymes and coenzyme Q(10) in a human oral cancer cell line with acquired bleomycin resistance.
    Yen HC; Li SH; Majima HJ; Huang YH; Chen CP; Liu CC; Tu YC; Chen CW
    Free Radic Res; 2011 Jun; 45(6):707-16. PubMed ID: 21486114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of three bleomycin-resistant human carcinoma cell lines and their cross-resistance to other antitumor agents.
    Urade M; Sugi M; Miyazaki T
    Cancer; 1988 Apr; 61(8):1501-7. PubMed ID: 2450630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.